Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human Apob100 x CETP transgenic mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1476-1483

  Zuckerman, Steven H ^a   Evans, Glenn F ^a   Schelm, Judi A ^a   Eacho, Patrick I ^a   Sandusky, George ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Apoproteins; Cholesterol; Estrogen; Lipoproteins; Transgenic

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL ESTER TRANSFER PROTEIN; ETHINYLESTRADIOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; AORTA ROOT; AORTA VALVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; FOAM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0033023371     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1476     Document Type: Article

References (40)

1. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325: 1196-1204.
2. Stamper MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekins CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurse's health study. N Engl J Med. 1991;325:756-762.
3. Grodstein F, Stampfer MJ, Colditz GA, Willet WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
4. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
5. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 1994;154:1106-1110.
6. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994;35:2083-2093.
7. Selzman CH, Whitehill TA, Shames BD, Pulido EJ, Cain BC, Harken AH. The biology of estrogen-mediated repair of cardiovascular injury. Ann Thorac Surg. 1998;65:868-874.
8. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase-dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 1996;126:65-75.
9. Zuckerman SH, Bryan-Poole N, Evans GF, Short L, Glasebrook AL. In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. Immunology. 1995;86:18-24.
10. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation. 1995;92:5-8.
11. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest. 1991;87:1274-1279.
12. Bourassa PAK, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 1996;93:10022-10027.
13. Huang Y, Schwendner SW, Rall SC Jr, Sanan DA, Mahley RW. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem. 1997;272:22685-22694.
14. Weinstein I, Wilcox HG, Heimberg M. Effects of high-dose ethinyl estradiol on serum concentrations and hepatic secretion of the very low density lipoprotein, triacylglycerol, cholesterol, and apolipoprotein A-I in the rat. Biochim Biophys Acta. 1986;876:450-459.
15. Wilson JN, Wilson SP, Eaton RP. Influence of genetic hyperlipidemia in the Zucker rat upon the lipemic response to graded estradiol exposure. Atherosclerosis. 1982;41:99-114.
16. Greenman DL, Fullerton FR, Suber R, Farmer J. Effects of purified (AIN-76A) and natural ingredient (NIH-07) diets on responses of Balb/c and B6C3F1 female mice to estradiol. J Toxicol Environ Health. 1987; 22:351-362.
17. Zuckerman SH, Bryan-Poole N. Estrogen-induced alterations in lipoprotein metabolism in autoimmune MRL/lpr mice. Arterioscler Thromb Vasc Biol. 1995;15:1556-1562.
18. Srivastava RAK, Baumann D, Schonfeld G. In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur J Biochem. 1993;216:527-538.
19. Srivastava RAK, Krul ES, Lin RC, Schonfeld G. Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms. Mol Cell Biochem. 1997; 173:161-168.
20. Smith JD, Breslow JL. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med. 1997;242: 99-109.
21. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, Tall AR. A mouse model with features of familial combined hyperlipidemia. Science. 1997;275:391-394.
22. Grass DS, Saini U, Felkner RH, Wallace RE, Lago WJP, Young SG, Swanson ME. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J Lipid Res. 1995;36:1082-1091.
23. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57:65-73.
24. Evans GF, Bensch WR, Apelgren LD, Bailey D, Kauffman RF, Bumol TF, Zuckerman SH. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution. J Lipid Res. 1994;35:1634-1645.
25. Tall A, Grenot E, Brocia R, Tabas I, Hesler C, Williams K, Denke M. Accelerated transfer of cholesteryl esters in dyslipidemic plasma, role of cholesteryl ester transfer protein. J Clin Invest. 1987;79:1217-1225.
26. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witzum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb Vasc Biol. 1994;14:605-616.
27. Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. Apo A-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39: 313-321.
28. Erickson SK, Jaeckle S, Lear SR, Brady SM, Havel RJ. Regulation of hepatic cholesterol and lipoprotein metabolism in ethinyl estradiol-treated rats. J Lipid Res. 1989;30:1763-1771.
29. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
30. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
31. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995;92:8264-8268.
32. Bird DA, Tangirala RK, Fruebis J, Steinberg D, Witzum JL, Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J Lipid Res. 1998;39:1079-1090.
33. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95:2246-2257.
34. Linton MF, Farese RV Jr, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein (a). J Clin Invest. 1993;92:3029-3037.
35. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest. 1995;96:1639-1646.
36. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, Losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625.
37. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, Quarfordt SH, Maeda N. Paradoxical enhancement of atherosclerosis by probuchol treatment in apolipoprotein E-deficient mice. J Clin Invest. 1997;99:2858-2866.
38. Liu J, Zhang YL, Spence MJ, Vestal RE, Wallace PM, Grass DS. Liver LDL receptor mRNA expression is decreased in human apoB/cETP double transgenic mice and is regulated by diet as well as the cytokine oncostatin M. Arterioscler Thromb Vasc Biol. 1997;17:2948-2954.
39. Srivastava RAK, Kitchens RT, Schonfeld G. Regulation of the apolipoprotein AIV gene expression by estrogen differs in rat and mouse. Eur J Biochem. 1994;222:507-514.
40. Srivastava RAK, Srivastava N, Averna M, Lin RC, Korach KS, Lubahn DB, Schonfeld G. Estrogen up-regulates apolipoprotein E (apo E) gene expression by increasing apo E mRNA in the translating pool via the estrogen receptor α-mediated pathway. J Biol Chem. 1997;272: 33360-33366.